299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-004063-21-NL (EUCTR)	24/07/2008	31/10/2007	An open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency. - N/A	An open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency. - N/A	Cystic fibrosis and pancreatic insufficiency MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis	Product Name: rhBSSL Product Code: rhBSSL INN or Proposed INN: Bucelipase alfa Trade Name: Nexium 20 Product Name: Nexium INN or Proposed INN: Esomeprazole	Biovitrum AB	NULL	Not Recruiting			Female: yes Male: yes	18		Netherlands
2	NCT01983774 (ClinicalTrials.gov)	February 2008	6/11/2013	Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations	Effect of Proton Pump Inhibitors on CF Exacerbations	Cystic Fibrosis	Drug: Esomeprazole;Drug: Placebo	Columbia University	NULL	Terminated	18 Years	65 Years	Both	13	Phase 2	United States